These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 30167757)
81. Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability. Maharao N; Venitz J; Gerk PM Biopharm Drug Dispos; 2019 Jan; 40(1):18-31. PubMed ID: 30520057 [TBL] [Abstract][Full Text] [Related]
82. Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. Schultze-Mosgau MH; Höchel J; Prien O; Zimmermann T; Brooks A; Bush J; Rottmann A Clin Pharmacokinet; 2018 Aug; 57(8):1001-1015. PubMed ID: 29330782 [TBL] [Abstract][Full Text] [Related]
83. Bioavailability of sublingual buprenorphine. Mendelson J; Upton RA; Everhart ET; Jacob P; Jones RT J Clin Pharmacol; 1997 Jan; 37(1):31-7. PubMed ID: 9048270 [TBL] [Abstract][Full Text] [Related]
84. Pharmacokinetics of transdermal buprenorphine patch in the elderly. Al-Tawil N; Odar-Cederlöf I; Berggren AC; Johnson HE; Persson J Eur J Clin Pharmacol; 2013 Feb; 69(2):143-9. PubMed ID: 22706617 [TBL] [Abstract][Full Text] [Related]
85. Pharmacokinetic comparison of two buprenorphine formulations after buccal administration in healthy male cats. Gulledge BM; Messenger KM; Cornell KK; Lindell H; Schmiedt CW J Feline Med Surg; 2018 Apr; 20(4):312-318. PubMed ID: 28569590 [TBL] [Abstract][Full Text] [Related]
86. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Ahonen J; Olkkola KT; Neuvonen PJ Eur J Clin Pharmacol; 1997; 51(5):415-9. PubMed ID: 9049584 [TBL] [Abstract][Full Text] [Related]
88. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. Nath RP; Upton RA; Everhart ET; Cheung P; Shwonek P; Jones RT; Mendelson JE J Clin Pharmacol; 1999 Jun; 39(6):619-23. PubMed ID: 10354966 [TBL] [Abstract][Full Text] [Related]
89. Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes. Moody DE; Fang WB; Lin SN; Weyant DM; Strom SC; Omiecinski CJ Drug Metab Dispos; 2009 Dec; 37(12):2323-9. PubMed ID: 19773542 [TBL] [Abstract][Full Text] [Related]
90. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Lukkari E; Juhakoski A; Aranko K; Neuvonen PJ Eur J Clin Pharmacol; 1997; 52(5):403-6. PubMed ID: 9272412 [TBL] [Abstract][Full Text] [Related]
91. Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. Gopal S; Tzeng TB; Cowan A Eur J Pharm Sci; 2002 Apr; 15(3):287-93. PubMed ID: 11923061 [TBL] [Abstract][Full Text] [Related]
92. The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl. Palkama VJ; Neuvonen PJ; Olkkola KT Br J Anaesth; 1998 Oct; 81(4):598-600. PubMed ID: 9924238 [TBL] [Abstract][Full Text] [Related]
93. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Luo X; Trevejo J; van Heeswijk RP; Smith F; Garg V Antimicrob Agents Chemother; 2012 Jul; 56(7):3641-7. PubMed ID: 22564847 [TBL] [Abstract][Full Text] [Related]
94. Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Moody DE; Fang WB; Morrison J; McCance-Katz E Drug Alcohol Depend; 2011 Nov; 118(2-3):479-83. PubMed ID: 21515002 [TBL] [Abstract][Full Text] [Related]
95. Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. Shen L; Wang J; Yi Y; Ye C; Wang R; Xia G; Yu C; Tu F; Xu J; Zheng Z Drug Test Anal; 2019 Apr; 11(4):595-600. PubMed ID: 30370647 [TBL] [Abstract][Full Text] [Related]
96. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Palkama VJ; Isohanni MH; Neuvonen PJ; Olkkola KT Anesth Analg; 1998 Jul; 87(1):190-4. PubMed ID: 9661572 [TBL] [Abstract][Full Text] [Related]
97. Pharmacokinetics of low-dose and high-dose buprenorphine in cats after rectal administration of different formulations. Schroers M; Meyer-Lindenberg A; Reese S; Dobenecker B; Pieper K J Feline Med Surg; 2019 Oct; 21(10):938-943. PubMed ID: 30427272 [TBL] [Abstract][Full Text] [Related]
98. Assessment of drug-drug interactions between voriconazole and glucocorticoids. Li M; Zhu L; Chen L; Li N; Qi F J Chemother; 2018 Sep; 30(5):296-303. PubMed ID: 30843777 [TBL] [Abstract][Full Text] [Related]
99. Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets ( Fitz CB; Goodroe AE; Moody DE; Fang WB; Capuano SV J Am Assoc Lab Anim Sci; 2021 Mar; 60(2):188-194. PubMed ID: 33375952 [TBL] [Abstract][Full Text] [Related]
100. Buprederm, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies. Park I; Kim D; Song J; In CH; Jeong SW; Lee SH; Min B; Lee D; Kim SO Pharm Res; 2008 May; 25(5):1052-62. PubMed ID: 18236140 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]